Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference
News provided byClearside Biomedical, Inc.
Sep 19, 2023, 7:05 AM ET
ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a panel discussion at the Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 2:10 p.m. ET in New York, NY.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com.
Investor and Media Contacts:
Source: Clearside Biomedical, Inc.
NOTE: This content is not written by or endorsed by "WRBL", its advertisers, or Nexstar Media Inc.